1. Introduction {#s0005}
===============

The term adenomatoid tumor (AT) was introduced by Golden and Ash ([@bb0030]) to describe a tumor with distinct morphologic features resembling an adenoma but having obscure histogenesis. Currently, ATs are considered to be specialized benign mesothelial tumors, ([@bb0025], [@bb0060]) usually found in the genital systems of both males and females, and only rarely reported in other sites such as the adrenal gland and peritoneum ([@bb0015]).With respect to uterine ATs, although three such ATs have been reported as occurring in renal transplant recipients under immunosuppression therapy, ([@bb0005], [@bb0010]) there has been no report suggesting that AT might occur frequently in renal transplant recipients under immunosuppression therapy.

2. Materials and methods {#s0010}
========================

We conducted a retrospective study of all patients who underwent total hysterectomy (all types, such as simple total hysterectomy, modified radical hysterectomy, and radical hysterectomy) at Nagoya Daini Red Cross Hospital during April 2003 through March 2011. All of the removed specimen materials were diagnosed by a pathologist. The epidemiologic and clinical manifestations of uterine ATs from immunosuppressed renal transplant recipients were analyzed.

This work was reviewed and approved by the Institutional Review Board of Nagoya Daini Red Cross Hospital. Informed consent was obtained from all patients.

Data were analyzed using SPSS version 21.0 (IBM, Armonk, NY, USA). Comparisons were assessed by the Fisher\'s exact test and the Mann-Whitney *U* test. The level of significance was selected at *P* \< 0.05.

3. Results {#s0015}
==========

There were 1094 total hysterectomies performed during the study period. Uterine ATs ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}) were found in 17 (1.55%) of the 1094 reviewed cases. Among the 17 patients (median age, 46 years; age range, 24--73 years) with uterine ATs, 10 (58.8%) were immunosuppressed renal transplant recipients ([Table 1](#t0005){ref-type="table"}). The other seven patients had no special medical history. Of the 17 cases of uterine AT, irregular menses was the main complaint in seven (41%), whereas three (18%) patients had reported hypermenorrhea, two (12%) had suffered dysmenorrhea, and two (12%) had asymptomatic swelling. Other patients had urinary retention or no symptoms, and in one patient, the AT was accidentally discovered via Porro\'s operation. Preoperatively, 12 patients were diagnosed with uterine leiomyomas, two with endometrial cancer, one with endometrial hyperplasia, one with pseudoaneurysm of the uterine artery, and one with ovarian cancer. None of the 1094 patients who underwent total hysterectomy were infected with human immunodeficiency virus (HIV). Moreover, none of the patients were diagnosed preoperatively with AT; all of the ATs were found in the hysterectomy specimens after surgery. It was difficult to investigate internal medication use among all patients.

Of the 1094 hysterectomy patients, 14 (1.28%) were immunosuppressed renal transplant recipients. Of these 14 immunosuppressed renal transplant recipients, 10 (71.4%) had uterine ATs, which were found in the hysterectomy specimens after surgery. A significant difference was observed between occurrence and non-occurrence of AT in the renal transplant recipients (*P* \< 0.001). The four renal transplant recipients without uterine ATs had undergone hysterectomy for uterine leiomyomas, cervical cancer, endometrial cancer, and hematometra ([Table 2](#t0010){ref-type="table"}). No differences regarding the medications were evident between the patients. All of the patients who received renal transplants had experienced onset of renal failure. In the 10 patients with AT, the causes of their renal failure were chronic glomerulonephritis (four patients), IgA nephropathy (three patients), pregnancy complication (one patient), membranoproliferative glomerulonephritis (one patient), and nephrotic syndrome (one patient). The causes of renal failure in the four patients without AT were IgA nephropathy, nephrosclerosis, thrombotic thrombocytopenic purpura, and unknown origin.

The median length of time each of the 14 renal transplant recipients who had been undergoing dialysis and the median duration from transplantation to hysterectomy. The 10 AT patients had received maintenance dialysis ranging in vintage from 7 to 172 months (median, 43 months) until undergoing kidney transplantation. Only one patient underwent temporary peritoneal dialysis. The four renal transplant recipients without AT had received hemodialysis ranging from 3 to 27 months (median vintage, 10.5 years). The occurrence of AT was significantly increased by the length of time on dialysis (*P* \< 0.047).

In the 10 renal transplant recipients with AT, the duration between their kidney transplant surgery and hysterectomy ranged from 67 to 284 months (median, 142.5 months). In the four renal transplant recipients without AT, the duration between their kidney transplant operation and hysterectomy ranged from 39 to 250 months (median, 62.5 months).

4. Discussion {#s0020}
=============

Adenomatoid tumors of the uterus are benign, rare lesions of the female genital tract. Their actual incidence may be higher than the recorded incidence because they are not usually biopsied due to their leiomyoma-like appearance and small size ([@bb0005]). The incidence of adenomatoid tumors in the uterus has been reported as between 0.1% and 1% ([@bb0065]). Although some cases of AT have been discovered preoperatively as large multicystic tumors, ([@bb0020], [@bb0045]) AT is difficult to discover preoperatively. In the present study, all cases of AT were incidental findings in hysterectomy specimens. One patient (5.88%) had a large cystic tumor ([Fig. 3](#f0015){ref-type="fig"}) with a diameter of 10 cm; the other 16 patients had small, solid tumors.

The rate of AT in this study (1.55%) was higher than that in previous studies ([@bb0065]). The reason could be that immunosuppressed renal transplant recipients have a predisposition for AT. In the present study, the rate of AT in the patients who were not immunosuppressed renal transplant recipients (0.65%) was the same as that in previous studies.

When we found that AT occurred frequently in renal transplant recipients under immunosuppression therapy, the first cause that came to mind was peritoneal dialysis. The mesothelium cells leak to the intraperitoneal spaces during peritoneal dialysis, ([@bb0040]) and it is suggested that AT is generated from the mesothelium ([@bb0025], [@bb0060]). We therefore conjectured that the cause could be attributed to peritoneal dialysis. However, among the patients of the present study, there was actually only one patient who had undergone temporary peritoneal dialysis.

A patient who receives hemodialysis is in a state of chronic inflammation ([@bb0035]). AT is frequently found with inflammation via pathological diagnosis. Some authors have reported that AT may have a posttraumatic or inflammatory origin; these investigators have proposed to stress the reactive, rather than the neoplastic, character of ATs ([@bb0045], [@bb0075], [@bb0070], [@bb0055]). The present study showed that the length of time on dialysis prior to renal transplantation is a risk factor for the development of adenomatoid tumors of the uterus.

There are approximately 300,000 end-stage renal disease patients who have received hemodialysis in Japan. Almost all patients receiving hemodialysis are waiting for a donor kidney. In our hospital, as a whole, 20% of cases, and 40% of recent cases, are performed as preemptive transplantation, which is a high level in Japan. None of the preemptive renal transplantation cases have supported the hypothesis that the length of time on dialysis before transplantation causes an increase in the incidence of AT.

There is a possibility that AT is a drug-induced disease caused by immunosuppressants. A recent report related AT to the immunosuppressed state in a patient with human immunodeficiency virus ([@bb0050]). Livingston et al. suggested that the extensive growth pattern of AT involving the entire myometrium, as well as its association with a component resembling multicystic mesothelioma, might reflect the patient\'s diminished ability to limit neoplastic processes ([@bb0005]). It could be that the immunosuppressed state might promote AT rather than the immunosuppressive drugs themselves.

There are several limitations in this study. First, this study is retrospective design in single-centre site. Second, the number of admitted patients with renal transplant recipient was small. Additionally, renal transplanted patients have a better follow-up than other patients, leading may be to higher hysterectomy rate and better data collection in this group.

The present study showed that renal transplantation with immunosuppression therapy and length of time on dialysis are risk factors for the development of adenomatoid tumors of the uterus. Further studies are needed to explore these possibilities.
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![Microscopic findings of adenomatoid tumor.\
Microscopically, the tumor is composed of ramifying tubular, cystic spaces made by non-atypical mesothelial-like cells between smooth muscle cells. These spaces are lined by cuboidal or flattened cells.](gr1){#f0005}

![Immunostain of adenomatoid tumor.\
Tubular formations lined by flattened cells are immunopositive for calretinin.](gr2){#f0010}

![Magnetic resonance imaging (MRI) scan of cystic adenomatoid tumor.\
The T2-weighted image revealed a 10.0-cm cystic tumor on the posterior wall of the uterus showing high signal intensity.](gr3){#f0015}

###### 

Characteristics of renal transplant recipients with adenomatoid tumor (AT).

Table 1

  Age at operation (y)   Age at dialysis (y)                      Age at transplant (y)                    Obstetrical status   Medicines     Presenting symptom   Original disease                           Preoperative diagnosis
  ---------------------- ---------------------------------------- ---------------------------------------- -------------------- ------------- -------------------- ------------------------------------------ -------------------------
  40                     27 36[a](#tf0005){ref-type="table-fn"}   27                                       Nulligravida         Unknown       Irregular menses     Chronic glomerulonephritis                 Myoma
  44                     30                                       30                                       Parturition 1        PSL Cys MZ    Hypermenorrhea       Chronic glomerulonephritis                 Myoma
  44                     33                                       34                                       Nulligravida         PSL Cys MMF   Irregular menses     Membranoproliferative glomerulonephritis   Myoma
  44                     24                                       32                                       Nulligravida         PSL Cys MZ    Irregular menses     Chronic glomerulonephritis                 Endometrial cancer
  46                     25                                       29 38[b](#tf0010){ref-type="table-fn"}   Parturition 2        PSL Cys       Urinary retention    Pregnancy nephropathy                      Myoma
  24                     8[c](#tf0015){ref-type="table-fn"}       11                                       Nulligravida         PSL TAC       Dysmenorrhea         Nephrotic syndrome                         Myoma
  58                     28                                       34                                       Parturition 1        PSL Cys MZ    Irregular menses     Chronic glomerulonephritis                 Endometrial hyperplasia
  52                     38                                       40                                       Nulligravida         PSL TAC       No symptoms          IgA nephropathy                            Myoma
  41                     30                                       36                                       Nulligravida         PSL Cys MMF   Hypermenorrhea       IgA nephropathy                            Myoma
  47                     33                                       35                                       Nulligravida         PSL Cys MMF   Irregular menses     IgA nephropathy                            Myoma

PSL, prednisolone; Cys, cyclosporine; MZ, mizoribine; MMF, mycophenolate mofetil; TAC, tacrolimus.

Renal function deteriorated after kidney transplantation, and patient received hemodialysis again.

Renal function deteriorated after kidney transplantation, and patient underwent transplantation again.

Peritoneal dialysis.

###### 

Characteristics of renal transplant recipients without adenomatoid tumor (AT).

Table 2

  Age at operation (y)   Age at dialysis (y)   Age at transplant (y)   Obstetrical status   Medicines     Presenting symptom   Primary renal condition               Preoperative diagnosis
  ---------------------- --------------------- ----------------------- -------------------- ------------- -------------------- ------------------------------------- ------------------------
  46                     25                    25                      Parturition 1        PSL Cys       Hypermenorrhea       Unknown                               Myoma
  51                     43                    43                      Nulligravida         PSL Cys MMF   No symptoms          IgA nephropathy                       Cervical cancer
  60                     55                    57                      Parturition 2        PSL Cys MMF   Irregular menses     Nephrosclerosis                       Endometrial cancer
  42                     36                    37                      Nulligravida         PSL TAC MMF   Irregular menses     Thrombotic thrombocytopenic purpura   Hematometra

PSL, prednisolone; Cys, cyclosporine; MMF, mycophenolate mofetil; TAC, tacrolimus.
